SEC Form 4 · accession 0001694187-19-000013
Neon Therapeutics, Inc. · NTGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard Gaynor
Officer — President of R&D
Period of report
Feb 27, 2019
Accepted (ET)
Mar 1, 2019 · 6:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001694187
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 27, 2019 | A | 57,500 | $0.00 | A | 146,822 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common StockF2 | $6.13 | Feb 27, 2019 | A | 105,000 | A | — | Feb 26, 2029 | Stock Option (Right to Buy) | 105,000 | 105,000 | D |
Explanation of responses
- F1Dr. Gaynor was awarded 57,500 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. The Restricted Stock Units shall vest annually over three years, with one-third vesting on the last day of February 2020 and the balance vesting in two equal annual installments thereafter, subject to the Reporting Person's continued service. The Restricted Stock Units may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
- F2This option shall vest and become exercisable in equal monthly installments over four years commencing on February 27, 2019.